When aged care becomes a short stay
As people look after themselves at home and go into care older, they "stay" for shorter periods. That is undermining the business model of aged care providers like Estia.
Sigma tapping growth opportunities: UBS upgrades
Sigma Pharmaceuticals is well placed to capitalise on growth opportunities, according to broker UBS, which has upgraded the company to a "buy."
Boggiano: the real estate whisperer of Southport
Estia Health's sale of apartments to its CFO Steven Boggiano is (another) bad look for the embattled aged-care service provider.
Quadrant turns up the Jetts on fitness play
Low-cost gym operator Jetts Fitness is shaping up to be the third leg of Quadrant Private Equity's push into Australia's fragmented health, fitness and wellness industries.
Sigma shares jump on hepatitis C windfall
Sigma Pharmaceuticals chief executive Mark Hooper estimates the government has spent about $1 billion subsidising new hepatitis C drugs in the past five months, but says the "unprecedented" cost is worth it.
Sigma lifts profit guidance
Sigma Pharmaceuticals expects full-year earnings growth of 10 per cent after lifting its half-year net profit by 25 per cent.
Macquarie cuts Estia, Japara price targets
Macquarie is the latest to cut price targets on aged care operators Estia Health, Japara Health and Regis Healthcare.
Estia's CFO grabs discount apartments
Estia Health has sold off apartments at big discounts and one of the buyers was its own CFO.
Bupa MD Dean Holden resigns
The head of Bupa's Australasian business Dean Holden will be replaced by Bupa UK managing director Richard Bowden.
Full house at Folkestone fund
The carnage in the listed aged care sector over the past week - as wary investors were spooked by government curbs on federal funding - has ...
